Critical Survey: Williston (OTCMKTS:WHCA) versus Inozyme Pharma (NASDAQ:INZY)

Inozyme Pharma (NASDAQ:INZY) and Williston (OTCMKTS:WHCA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Inozyme Pharma and Williston, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inozyme Pharma	0	0	9	0	3.00
Williston	0	0	0	0	0.00

Inozyme Pharma presently has a consensus target price of $18.33, suggesting a potential upside of 1,114.13%. Given Inozyme Pharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Inozyme Pharma is more favorable than Williston.

Valuation & Earnings

This table compares Inozyme Pharma and Williston”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inozyme Pharma	N/A	N/A	-$71.17 million	($1.56)	-0.97
Williston	N/A	N/A	N/A	N/A	N/A

Profitability

This table compares Inozyme Pharma and Williston’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inozyme Pharma	N/A	-88.42%	-57.02%
Williston	N/A	N/A	N/A

Risk & Volatility

Inozyme Pharma has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, Williston has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.

Institutional and Insider Ownership

88.3% of Inozyme Pharma shares are held by institutional investors. 11.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Inozyme Pharma beats Williston on 5 of the 8 factors compared between the two stocks.

About Inozyme Pharma

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.